01975nas a2200217   4500000000100000008004100001653003900042653002500081653003500106653001600141653001400157100001500171700001200186700001200198700001300210700001400223245009100237300001000328490001300338520140600351       2018                            d10aNeglected tropical diseases (NTDs)10aLymphatic filariasis10amass drug administration (MDA)10aElimination10aTreatment1 aGyapong JO1 aOwusu I1 aVroom F1 aMensah E1 aGyapong M00aElimination of lymphatic filariasis: current perspectives on mass drug administration.  a18-330 vVolume 93 aFollowing the London declaration on neglected tropical diseases (NTDs) in 2012 and inspired by the WHO 2020 roadmap to control or eliminate NTDs, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) intensified preventive chemotherapy and management of morbidity as the two main strategies to enhance progress towards the elimination of lymphatic filariasis (LF). This paper focuses on current perspectives of mass drug administration (MDA) towards the elimination of LF. The goal of MDA is to reduce the density of parasites circulating in the blood of infected persons and the intensity of infection in communities to levels where transmission is no longer sustainable by the mosquito vector. Three drugs, diethylcarbamazine, albendazole, and ivermectin are currently available for LF treatment, and their effectiveness and relative safety have opened the possibility of treating the entire population at risk. Currently, almost all LF endemic countries rely on the single-dose two-drug regimen recommended by the GPELF to achieve elimination. The 4th WHO report on NTDs has indicated that considerable progress has been made towards elimination of LF in some countries while acknowledging some challenges. In this review, we conclude that the 2020 elimination goal can be achieved if issues pertaining to the drug distribution, health system and implementation challenges are addressed.